Redwood Pharma AB announced that The results of Redwood Pharma's Phase II study of RP101 have now been published in the medical journal Advances in Therapy and will also be presented as a scientific poster presentation at the forthcoming annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). In 2020, Redwood Pharma completed a Phase II clinical trial in Europe of RP101, the company's drug candidate for the treatment of chronic dry eye in post-menopausal women. The results have now been published in Advances in Therapy, an international scientific journal in clinical medicine. The results of Redwood Pharma's Phase II trial of RP 101 will also be presented in a poster presentation at the upcoming virtual annual meeting of the US-based research organization Association for Research in Vision and Ophthalmology on ??May 1-7. ARVO is one of the world's largest and most respected research organizations in the field of vision and eyes and has almost 11,000 researchers globally.